MSX-122

MSX-122 is an orally bioavailable small molecule that acts as a partial antagonist of the chemokine receptor CXCR4. By binding to CXCR4, it prevents the interaction with its ligand stromal derived factor 1 (SDF‑1 or CXCL12), thereby inhibiting receptor activation. This mechanism can result in decreased tumor cell proliferation and migration, and has potential antineoplastic and antiviral activities. Preclinical studies have shown that MSX‑122 reduces metastasis in various cancer models and blocks processes such as chemotaxis, cAMP modulation, and inflammatory cytokine production. It was developed for investigational use in solid tumors but failed clinical trials due to unmanageable toxicities[1][2][3][5][6][7].

Other names

N,N'-(1,4-phenylenebis(methylene))bis(pyrimidin-2-amine)CXCR4 inhibitor Q-122CXCR-4 inhibitor Q-122CXCR 4 inhibitor Q-122